Publication | Closed Access
JET-HCC: A phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinoma
21
Citations
0
References
2017
Year
OncologyHepatologyMedicinePathologyPlacebo-controlled StudyPharmacotherapyLiver CancerCancer TreatmentSecond-line TherapyPharmacologyRadiation OncologyHepatocellular CarcinomaPhase 3
No additional data available for this publication yet. Check back later!